Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Med ; 22(1): 76, 2024 Feb 20.
Artigo em Inglês | MEDLINE | ID: mdl-38378544

RESUMO

BACKGROUND: To combat the opioid crisis, interventions targeting the opioid prescribing behaviour of physicians involved in the management of patients with chronic non-cancer pain (CNCP) have been introduced in clinical settings. An integrative synthesis of systematic review evidence is required to better understand the effects of these interventions. Our objective was to synthesize the systematic review evidence on the effect of interventions targeting the behaviours of physician opioid prescribers for CNCP among adults on patient and population health and prescriber behaviour. METHODS: We searched MEDLINE, Embase, and PsycInfo via Ovid; the Cochrane Database of Systematic Reviews; and Epistemonikos. We included systematic reviews that evaluate any type of intervention aimed at impacting opioid prescriber behaviour for adult CNCP in an outpatient setting. RESULTS: We identified three full texts for our review that contained 68 unique primary studies. The main interventions we evaluated were structured prescriber education (one review) and prescription drug monitoring programmes (PDMPs) (two reviews). Due to the paucity of data available, we could not determine with certainty that education interventions improved outcomes in deprescribing. There is some evidence that PDMPs decrease the number of adverse opioid-related events, increase communication among healthcare workers and patients, modify healthcare practitioners' approach towards their opioid prescribed patients, and offer more chances for education and counselling. CONCLUSIONS: Our overview explores the possibility of PDMPs as an opioid deprescribing intervention and highlights the need for more high-quality primary research on this topic.


Assuntos
Dor Crônica , Médicos , Adulto , Humanos , Analgésicos Opioides/efeitos adversos , Dor Crônica/tratamento farmacológico , Padrões de Prática Médica , Revisões Sistemáticas como Assunto , Prescrições de Medicamentos
2.
NPJ Prim Care Respir Med ; 32(1): 45, 2022 10 22.
Artigo em Inglês | MEDLINE | ID: mdl-36273009

RESUMO

Given the increasing use of e-cigarettes and uncertainty surrounding their safety, we conducted a systematic review to determine the effects of e-cigarettes on measures of lung function. We systematically searched EMBASE, MEDLINE, and PsycINFO databases via Ovid, the Cochrane CENTRAL database, and the Web of Science Core from 2004 until July 2021, identifying 8856 potentially eligible studies. A total of eight studies (seven studying immediate effects and one long-term effects, 273 total participants) were included. The risk of bias was assessed using the Risk of Bias in Non-randomized Studies-of Interventions (ROBINS-I) and Cochrane risk of bias tools. These studies suggest that vaping increases airway resistance but does not appear to impact forced expiratory volume in one second (FEV1), forced vital capacity (FVC), or FEV1/FVC ratio. However, given the limited size and follow-up duration of these studies, larger, long-term studies are required to further determine the effects of e-cigarettes on lung function.


Assuntos
Sistemas Eletrônicos de Liberação de Nicotina , Vaping , Humanos , Vaping/efeitos adversos , Volume Expiratório Forçado , Capacidade Vital , Pulmão
3.
J Parkinsons Dis ; 11(3): 1409-1416, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33967057

RESUMO

BACKGROUND: Depression and anxiety are common in synucleinopathies and often present during prodromal stages, including idiopathic/isolated REM sleep behavior disorder (iRBD). However, the specific profiles of depression/anxiety and their predictive values for phenoconversion remain unclear. OBJECTIVE: To assess the predominant manifestations, predictive value, and changes over time in depressive and anxiety symptoms in iRBD. METHODS: Patients with polysomnography-confirmed iRBD (n = 114) and healthy controls (n = 44) were recruited. The Beck Depression Inventory and Beck Anxiety Inventory were administered at baseline, which was repeated prospectively over follow-up. Factor solutions were generated to delineate symptom clusters within the scales, and to help disentangle primary mood symptoms from other neurodegenerative confounds. Total scores, individual scale items, and factors were evaluated to 1) compare patients and controls, 2) assess progression of symptoms over time, and 3) assess predictive value for phenoconversion. RESULTS: At baseline, iRBD patients had more severe depressive (9.0 = 6.7 vs 5.8 = 4.8) and anxiety (7.0 = 7.9 vs 4.5 = 6.0) symptoms than controls. Increased scores were seen in numerous individual scale items and most scales' factors. For depressive symptoms, there was no progression of total scores or factors over time. However, anxiety scores worsened slightly over prospective follow-up (annual slope = 0.58 points, p < 0.05). Over an average 2.4 = 3.1-year follow-up, 37 patients phenoconverted and 72 remained disease-free. Neither baseline depressive nor anxiety symptoms predicted phenoconversion to clinical neurodegenerative disease. CONCLUSIONS: Depressive and anxiety symptoms are common in iRBD. However, they do not predict phenoconversion and show only modest progression over time, solely for anxiety.


Assuntos
Ansiedade , Depressão , Transtorno do Comportamento do Sono REM , Ansiedade/epidemiologia , Depressão/epidemiologia , Humanos , Estudos Prospectivos , Transtorno do Comportamento do Sono REM/psicologia
4.
Parkinsonism Relat Disord ; 75: 76-79, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32492550

RESUMO

BACKGROUND: Though visual illusions and hallucinations are common in dementia with Lewy bodies (DLB) and Parkinson's disease (PD), they are not typically observed clinically in prodromal stages, including isolated REM sleep behavior disorder (iRBD). False-noise errors on the pareidolia test (seeing faces when none are present) may be an effective measure of susceptibility to future hallucinations in iRBD. METHODS: One hundred patients with iRBD underwent the 20-image pareidolia test. Clinical markers were assessed and a neuropsychological battery was administered. An exploratory analysis on the impact of pareidolic errors on phenoconversion was also performed. RESULTS: In our cohort, 17 patients (17%) made false-noise pareidolic errors. These patients had significantly lower total Montreal Cognitive Assesment (MoCA) scores (26.7 ± 2.3 vs. 24.4 ± 2.6, B = -1.88, 95% CI: [-3.17, -0.59]), with lower subcomponent MoCA scores on memory and visuospatial-executive sections. Pareidolic errors were also associated with lower visuospatial, attention/executive, and memory scores on the neuropsychological tests. Furthermore, after 1.6 years follow-up, 3/16 (19%) patients making pareidolic errors had phenoconverted at time of publication compared to 6/71 (8%) patients who did not make errors. CONCLUSION: Pareidolic errors in patients with iRBD are associated with poorer overall cognition and may indicate higher risk of DLB.


Assuntos
Disfunção Cognitiva/fisiopatologia , Reconhecimento Facial/fisiologia , Transtornos da Percepção/fisiopatologia , Transtorno do Comportamento do Sono REM/fisiopatologia , Idoso , Disfunção Cognitiva/etiologia , Feminino , Humanos , Doença por Corpos de Lewy/fisiopatologia , Masculino , Pessoa de Meia-Idade , Transtornos da Percepção/etiologia , Transtorno do Comportamento do Sono REM/complicações , Risco
5.
Parkinsonism Relat Disord ; 65: 230-233, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31076265

RESUMO

BACKGROUND: Mutations in the glucocerebrosidase (GBA) gene are strongly associated with REM sleep behavior disorder (RBD). It is unclear whether GBA mutations might affect clinical phenotype or rate of phenoconversion to parkinsonism or dementia. METHODS: We sequenced GBA in polysomnographic-proven idiopathic RBD (iRBD) patients. The effect of GBA mutations on clinical neurodegenerative markers and phenoconversion rate was assessed. RESULTS: Of 102 patients sequenced, 13 (13%) had GBA mutations and 89 did not. Aside from lower self-reported age of RBD onset in subjects with GBA mutations, no significant differences were observed in any clinical marker between patients with and without mutations. However, GBA mutations were associated with 3.2-fold higher phenoconversion rate from RBD to parkinsonism and/or dementia (95% CI = 1.4-7.3, p = 0.006). CONCLUSION: Although GBA mutations do not appear to affect clinical neurodegenerative markers (and thus are not differentiable as an independent subtype of iRBD), they may accelerate the conversion of RBD to defined neurodegenerative synucleinopathy.


Assuntos
Demência/genética , Progressão da Doença , Glucosilceramidase/genética , Transtornos Parkinsonianos/genética , Transtorno do Comportamento do Sono REM/genética , Idoso , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Mutação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...